Oncotelic Therapeutics
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$14.19M
-1.1
$280K
26
Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is headquartered in Agoura Hills, California and currently employs 26 full-time employees. The firm has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.
emptyResult
Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is headquartered in Agoura Hills, California and currently employs 26 full-time employees. The firm has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.
Recently from Cashu
Oncotelic Therapeutics: Revolutionizing Oncology with Deciparticle™ Nanomedicine Innovations
Oncotelic Therapeutics: Pioneering Innovations in Nanomedicine for Oncology Oncotelic Therapeutics Inc. is at the forefront of revolutionizing oncology treatment through its groundbreaking Deciparticl…
Oncotelic Therapeutics: Pioneering Nanomedicine for Enhanced Cancer Drug Delivery
Oncotelic Therapeutics: Transforming Oncology with Advanced Drug Delivery Oncotelic Therapeutics Inc. is at the forefront of revolutionizing cancer treatment through its innovative Deciparticle(TM) pl…
Oncotelic Therapeutics: Innovating RNA Medicines for Aggressive Cancers and Rare Diseases
Oncotelic Therapeutics: Pioneering Solutions for Unmet Medical Needs in Oncology Oncotelic Therapeutics Inc., under the leadership of CEO Dr. Vuong Trieu, is making significant strides in the field of…